AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36096487 — intervention group
Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (IAP) during HIPEC (<18 mmHg)
Number of subjects: 40
Study 36096487 — intervention group
Group type: EXPERIMENTAL
Intervention: High IAP during HIPEC
Number of subjects: 40
Study 36096487 — intervention group
Group type: COMPARATOR
Intervention: Low IAP during HIPEC
Number of subjects: 40
Study 34273733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth facemask (CM)
Number of subjects: 20
Study 34273733 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical facemask (SM)
Number of subjects: 20
Study 34273733 — intervention group
Group type: COMPARATOR
Intervention: No mask (NM)
Number of subjects: 20
Study 34273733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth facemask (CM) and Surgical facemask (SM)
Number of subjects: 20
Study 35616359 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrity intervention program using moral integrity stories
Number of subjects: 200
Study 35616359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 33275962 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided SSNB using a proximal approach (n=23)
Number of subjects: 47
Study 33275962 — intervention group
Group type: COMPARATOR
Intervention: US-guided SSNB using a distal approach (n=24)
Number of subjects: 47
Study 33825723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pletax® (cilostazol) 100 mg twice daily
Number of subjects: 100
Study 33825723 — intervention group
Group type: COMPARATOR
Intervention: Trental® (pentoxifylline) 400 mg three times daily
Number of subjects: 100
Study 33825723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pletax® (cilostazol)
Number of subjects: 100
Study 33825723 — intervention group
Group type: COMPARATOR
Intervention: Trental® (pentoxifylline)
Number of subjects: 100
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver handwashing after handling animals
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver handwashing before eating
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohabitation with domestic animals
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in a household with vinyl-covered dirt floors
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver handwashing after child or self-defecation
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Private latrine access
Number of subjects: 898
Study 36316067 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared sanitation access without handwashing
Number of subjects: 898
Study 33909055 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based assistive tool
Number of subjects: 40
Study 35468159 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional IVF
Number of subjects: 30
Study 35468159 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 30
Study 35468159 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygotes biopsied on day 5/6
Number of subjects: 30
Study 35468159 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocysts biopsied on day 5
Number of subjects: 30
Study 34855311 — intervention group
Group type: EXPERIMENTAL
Intervention: H. psudoplicatum supplementation (250 mg/day for 6 weeks)
Number of subjects: 50
Study 34855311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg/day for 6 weeks)
Number of subjects: 50
Study 35172981 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM (Managing Cancer and Living Meaningfully) therapy
Number of subjects: 195
Study 35172981 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 195
Study 32851435 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Response Short Answer Questions (FRSAQs) test
Number of subjects: 109
Study 32851435 — intervention group
Group type: COMPARATOR
Intervention: Traditional spot test
Number of subjects: 109
Study 32851435 — intervention group
Group type: EXPERIMENTAL
Intervention: FRSAQs spot test
Number of subjects: 109
Study 32851435 — intervention group
Group type: COMPARATOR
Intervention: FRSAQs vs Traditional spot test
Number of subjects: 109
Study 35472303 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for AF using a 2-week single-lead electrocardiographic patch monitor
Number of subjects: 11931
Study 35472303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 11931
Study 33034770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 73
Study 33034770 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical clipping
Number of subjects: 73
Study 35420551 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-containing vaginal ring
Number of subjects: 39
Study 35420551 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 39
Study 34097044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of BNT162b2 vaccine
Number of subjects: 503875
Study 34543417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir treatment (12-week course)
Number of subjects: 144
Study 34543417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherence (taking <90% of doses)
Number of subjects: 144
Study 34543417 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (taking ≥90% of doses)
Number of subjects: 144
Study 34543417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherence
Number of subjects: 144
Study 35389391 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich soybean oil (SO)
Number of subjects: 90
Study 35389391 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich olive oil (OO)
Number of subjects: 90
Study 35389391 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich camellia seed oil (CSO)
Number of subjects: 90
Study 34292792 — intervention group
Group type: EXPERIMENTAL
Intervention: T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg followed by durvalumab 1,500 mg once every 4 weeks)
Number of subjects: 332
Study 34292792 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy (1,500 mg once every 4 weeks)
Number of subjects: 332
Study 34292792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab monotherapy (750 mg once every 4 weeks for seven doses, then once every 12 weeks)
Number of subjects: 332
Study 34292792 — intervention group
Group type: EXPERIMENTAL
Intervention: T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks for four doses, then durvalumab 1,500 mg once every 4 weeks)
Number of subjects: 332
Study 35692047 — intervention group
Group type: EXPERIMENTAL
Intervention: CETEG (lomustine and temozolomide) followed by partial brain radiotherapy (RT) plus PCV (RT-PCV) at progression
Number of subjects: 182
Study 35692047 — intervention group
Group type: COMPARATOR
Intervention: Partial brain radiotherapy (RT) followed by procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV)
Number of subjects: 182
Study 35692047 — intervention group
Group type: COMPARATOR
Intervention: Best investigators choice (BIC) at progression
Number of subjects: 182
Study 35692047 — intervention group
Group type: EXPERIMENTAL
Intervention: CETEG (lomustine and temozolomide)
Number of subjects: 182
Study 35692047 — intervention group
Group type: COMPARATOR
Intervention: RT-PCV
Number of subjects: 182
Study 33421091 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A IUD
Number of subjects: 140
Study 33421091 — intervention group
Group type: COMPARATOR
Intervention: LNG IUS
Number of subjects: 140
Study 33421091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 140
Study 33421091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 140
Study 33421091 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-placental IUD insertion
Number of subjects: 140
Study 34494357 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Remediation Therapy (MCR)
Number of subjects: 73
Study 34494357 — intervention group
Group type: COMPARATOR
Intervention: Control (non-participation in MCR)
Number of subjects: 73
Study 34256958 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket Shield Technique (SST)
Number of subjects: 27
Study 34256958 — intervention group
Group type: COMPARATOR
Intervention: Minimally Traumatic Extraction Approach
Number of subjects: 27
Study 35587680 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified comfortable nursing
Number of subjects: 128
Study 35587680 — intervention group
Group type: COMPARATOR
Intervention: Conventional four‐handed operation nursing
Number of subjects: 128
Study 35025539 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Therapy (SET)
Number of subjects: 100
Study 35025539 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 100
Study 34962514 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination with an Allied Health Liaison Officer
Number of subjects: 81
Study 34962514 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study 34087060 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' diabetes self-management education using Japan Association of Diabetes Education and Care education tool and SMBG analyzer
Number of subjects: 76
Study 34087060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no use of Japan Association of Diabetes Education and Care education tool and SMBG analyzer)
Number of subjects: 76
Study 34087060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 34087060 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 32924560 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 88
Study 32924560 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 88
Study 35485657 — intervention group
Group type: COMPARATOR
Intervention: Training on a stabiloplatform with biofeedback (BFB)
Number of subjects: 40
Study 35485657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular gymnastics
Number of subjects: 40
Study 35291853 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 77
Study 35291853 — intervention group
Group type: COMPARATOR
Intervention: Written education
Number of subjects: 77
Study 34404446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and internet‐delivered psychological intervention (psychologically informed physical treatments)
Number of subjects: 25
Study 34404446 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study 32453835 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 1.5 h psychoeducation intervention and a set of booklets
Number of subjects: 215
Study 32453835 — intervention group
Group type: COMPARATOR
Intervention: Set of booklets only
Number of subjects: 215
Study 35523955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 577
Study 35523955 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 577
Study 34273498 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on dry powder inhalation (DPI) of combined anti-TB therapy (isoniazid 5 mg, rifampicin 2 mg, pyrazinamide 16 mg, levofloxacin 2 mg)
Number of subjects: 91
Study 34273498 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on dry powder inhalation (DPI) of combined anti-TB therapy
Number of subjects: 91
Study 34273498 — intervention group
Group type: COMPARATOR
Intervention: Placebo DPI
Number of subjects: 91
Study 36217134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum appliance
Number of subjects: 40
Study 36217134 — intervention group
Group type: COMPARATOR
Intervention: Clear Aligners
Number of subjects: 40
Study 34684591 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS1 + DC
Number of subjects: 321
Study 34684591 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS2 + DC
Number of subjects: 321
Study 34684591 — intervention group
Group type: COMPARATOR
Intervention: DC only
Number of subjects: 321
Study 33213541 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (SSRI)
Number of subjects: 0
Study 33213541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (NDRI)
Number of subjects: 0
Study 33213541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34339684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure with backup rate
Number of subjects: 0
Study 34339684 — intervention group
Group type: EXPERIMENTAL
Intervention: Home mechanical ventilators
Number of subjects: 0
Study 34339684 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed recommendations for noninvasive ventilation access
Number of subjects: 0
Study 32660350 — intervention group
Group type: EXPERIMENTAL
Intervention: High status condition
Number of subjects: 6426
Study 32660350 — intervention group
Group type: COMPARATOR
Intervention: Low status condition
Number of subjects: 6426
Study 32660350 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-class individuals
Number of subjects: 6426
Study 32660350 — intervention group
Group type: COMPARATOR
Intervention: Working-class individuals
Number of subjects: 6426
Study 36096430 — intervention group
Group type: EXPERIMENTAL
Intervention: SpikoGen® vaccine
Number of subjects: 16876
Study 33840531 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-mediated photobiomodulation (850 nm wavelength, 60 mW/cm2 power, continuous LED for 5 min/d)
Number of subjects: 20
Study 33840531 — intervention group
Group type: COMPARATOR
Intervention: No photobiomodulation (control side)
Number of subjects: 20
Study 35574009 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the abdomen
Number of subjects: 8
Study 35574009 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the upper arm
Number of subjects: 8
Study 35574009 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the thigh
Number of subjects: 8
Study 32238335 — intervention group
Group type: EXPERIMENTAL
Intervention: One-way text messages
Number of subjects: 705
Study 32238335 — intervention group
Group type: COMPARATOR
Intervention: No text messages (Control)
Number of subjects: 705
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of instrumental support seeking
Number of subjects: 564
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of proactive coping
Number of subjects: 564
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of emotional support seeking
Number of subjects: 564
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (drug-use-related disorders)
Number of subjects: 564
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (unemployment)
Number of subjects: 564
Study 34082633 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (younger age)
Number of subjects: 564
Study 32979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided self-help
Number of subjects: 0
Study 32979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week guided self-help
Number of subjects: 0
Study 32979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week pure self-help
Number of subjects: 0
Study 32979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided self-help with access to a discussion forum
Number of subjects: 0
Study 32979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided self-help without access to a discussion forum
Number of subjects: 0
Study 32979230 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study 36434514 — intervention group
Group type: EXPERIMENTAL
Intervention: ZYN002 (cannabidiol transdermal gel) 250 mg or 500 mg daily for 12 weeks
Number of subjects: 212
Study 36434514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 34651093 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 120
Study 34651093 — intervention group
Group type: COMPARATOR
Intervention: Dorsal locking nail-plate
Number of subjects: 120
Study 34651093 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plate and Dorsal locking nail-plate
Number of subjects: 120
Study 32583085 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for semantic image segmentation
Number of subjects: 43
Study 32583085 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) on BrainWeb data set
Number of subjects: 43
Study 32583085 — intervention group
Group type: COMPARATOR
Intervention: Classical FAST algorithm on BrainWeb data set
Number of subjects: 43
Study 36160788 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton’s Four‐Step Approach
Number of subjects: 186
Study 36160788 — intervention group
Group type: COMPARATOR
Intervention: Standard bedside teaching (Control)
Number of subjects: 186
Study 32251729 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0
Study 32251729 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35050705 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based visual-acoustic biofeedback using Speech Therapist's App for /r/ Treatment
Number of subjects: 4
Study 35050705 — intervention group
Group type: COMPARATOR
Intervention: Nonbiofeedback treatment using Speech Therapist's App for /r/ Treatment
Number of subjects: 4
Study 36205492 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty Communication Education Module (training in communication skills)
Number of subjects: 109
Study 36205492 — intervention group
Group type: COMPARATOR
Intervention: Delayed access (no intervention at T2)
Number of subjects: 109
Study 33191408 — intervention group
Group type: EXPERIMENTAL
Intervention: Belotecan (0.5 mg/m2)
Number of subjects: 164
Study 33191408 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2)
Number of subjects: 164
Study 35820814 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physiological recruitment maneuver (CPRM) with sigh in lateral position
Number of subjects: 70
Study 35820814 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 70
Study 33662163 — intervention group
Group type: EXPERIMENTAL
Intervention: real-tDCS (right anodal/left cathodal)
Number of subjects: 17
Study 33662163 — intervention group
Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 17
Study 32820015 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib + 7+3 (cytarabine + daunorubicin)
Number of subjects: 53
Study 34441026 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dentures with vitamin B12
Number of subjects: 252
Study 34441026 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 252
Study 33203854 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T; N = 34)
Number of subjects: 128
Study 33203854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (L; N = 36)
Number of subjects: 128
Study 33203854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trastuzumab and lapatinib (TL; N = 58)
Number of subjects: 128
Study 32803294 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine inhalation therapy (2400 mg daily for 8 weeks)
Number of subjects: 120
Study 34461811 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation sites and genes
Number of subjects: 0
Study 34461811 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal pathways in the brain
Number of subjects: 0
Study 34461811 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal pathways in the blood
Number of subjects: 0
Study 34461811 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation influence on gene expression
Number of subjects: 0
Study 34461811 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation of gene expression
Number of subjects: 0
Study 32899129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release protein substitute
Number of subjects: 13
Study 35654284 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 210
Study 35654284 — intervention group
Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 210
Study 34697956 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (34 patients)
Number of subjects: 89
Study 34697956 — intervention group
Group type: COMPARATOR
Intervention: Handout group (37 patients)
Number of subjects: 89
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for in-hospital death
Number of subjects: 31157
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for chronic lung disease
Number of subjects: 31157
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for intraventricular hemorrhage (grade III or IV)
Number of subjects: 31157
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for periventricular leukomalacia
Number of subjects: 31157
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for cerebral palsy at 3 years of age
Number of subjects: 31157
Study 33656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for developmental quotient of <70 at 3 years of age
Number of subjects: 31157
Study 32800493 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Number of subjects: 1493
Study 32800493 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO)
Number of subjects: 1493
Study 32800493 — intervention group
Group type: COMPARATOR
Intervention: 6 × 5-fluorouracil, epirubicin, and cyclophosphamide (FEC120)
Number of subjects: 1493
Study 32800493 — intervention group
Group type: COMPARATOR
Intervention: 4 × epirubicin and cyclophosphamide followed by 4 × docetaxel (EC-DOC)
Number of subjects: 1493
Study 32800493 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fatigue level
Number of subjects: 1493
Study 36201995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 137